Potential side effects in patients treated with inhaled corticosteroids and long-acting beta2-agonists
- PMID: 19136239
- DOI: 10.1016/j.rmed.2008.10.028
Potential side effects in patients treated with inhaled corticosteroids and long-acting beta2-agonists
Abstract
Background: Long-acting-beta-agonists and inhaled corticosteroids are widely used in patients with obstructive lung disease. We determined the occurrence of potential side effects to inhaled steroids and long-acting-beta-agonists in an open post-marketing observational study.
Methods: A total of 158 adult patients treated with long-acting-beta-agonists and inhaled steroids because of asthma or chronic obstructive lung disease were included prospectively in a cross-sectional study from September 2004 through august 2005. A subgroup of 31 patients with minimal disease were observed prospectively after treatment reduction. The frequency and intensity of potential side effects to long-acting-beta-agonists and inhaled corticosteroids were registered on a 10-point visual analogue scale.
Results: A total of 131 (83%) reported potential side effects to inhaled steroids. The most frequent were sore (54%) and dry (52%) throat. A total of 114 (72%) patients reported potential side effects to long-acting-beta-agonists. The most frequent were muscle cramps (62%) and muscle twisting (39%). For 5/8 potential side effects their occurrence increased with increased individual dozing. In 31 patients the mean medication with steroids and long-acting-beta-agonists was reduced by 87% and 97.5%, respectively, with side effects reduced by 62% (p<0.001) to inhaled steroids and by 91% (p<0.001) to inhaled long-acting-beta-agonists.
Conclusions: Potential side effects in adult patients to inhaled corticosteroids and long-acting-beta-agonists are very common with increased frequency with increased dozing. Patients are largely unaware of the association. Patients should be better informed, and the results further support tailored dozing to minimum therapy.
Similar articles
-
Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.Pharmacotherapy. 2009 Aug;29(8):891-905. doi: 10.1592/phco.29.8.891. Pharmacotherapy. 2009. PMID: 19637942
-
Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.Semin Respir Crit Care Med. 2010 Jun;31(3):321-33. doi: 10.1055/s-0030-1254072. Epub 2010 May 21. Semin Respir Crit Care Med. 2010. PMID: 20496301 Review.
-
[Combination treatment with inhaled corticosteroid/long-acting beta 2-adrenergic bronchodilator in the treatment of asthma].Nihon Rinsho. 2001 Oct;59(10):1992-9. Nihon Rinsho. 2001. PMID: 11676144 Review. Japanese.
-
[Efficacy and safety of salmeterol (50 microgram) and fluticasone (250 microgram) in a single inhaler device (diskus) in patients with mild to moderate asthma].Pneumologie. 2002 Feb;56(2):91-7. doi: 10.1055/s-2002-20089. Pneumologie. 2002. PMID: 11842346 German.
-
Higher patient perceived side effects related to higher daily doses of inhaled corticosteroids in the community: a cross-sectional analysis.Respir Med. 2006 Aug;100(8):1318-36. doi: 10.1016/j.rmed.2005.11.029. Epub 2006 Jan 25. Respir Med. 2006. PMID: 16442275
Cited by
-
Local adverse effects associated with the use of inhaled corticosteroids in patients with moderate or severe asthma.J Bras Pneumol. 2013 Jun-Aug;39(4):409-17. doi: 10.1590/S1806-37132013000400003. J Bras Pneumol. 2013. PMID: 24068261 Free PMC article.
-
Chronic cough: new insights and future prospects.Eur Respir Rev. 2021 Nov 30;30(162):210127. doi: 10.1183/16000617.0127-2021. Print 2021 Dec 31. Eur Respir Rev. 2021. PMID: 34853095 Free PMC article. Review.
-
Efficacy and Safety of Superior Laryngeal Nerve Block in the Management of Neuropathic Cough: A Systematic Review.Lung. 2025 May 22;203(1):63. doi: 10.1007/s00408-025-00819-1. Lung. 2025. PMID: 40402261 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical